Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815301 | 0.94 | EPHX2 (0.41) | HCRTR2HCRTR1EPHX2 | |
| SCHEMBL14815100 | 0.89 | HCRTR2 (0.41) | HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14815323 | 0.85 | HCRTR2 (0.43) | HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14815549 | 0.83 | EPHX2 (0.41) | HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14815213 | 0.81 | HCRTR2 (0.41) | HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14815401 | 0.80 | MGLL (0.37) | HCRTR2IRAK4 | |
| SCHEMBL14815468 | 0.77 | EPHX2 (0.46) | HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14815186 | 0.75 | CYP3A4 (0.42) | HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14815518 | 0.74 | PHGDH (0.41) | HCRTR2HCRTR1 | |
| SCHEMBL14815099 | 0.74 | EPHX2 (0.39) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | HCRTR2 434/4885HCRTR1 654/4885CYP3A4 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.